Laurion Capital Management’s Viking Therapeutics VKTX Stock Holding History

Laurion Capital Management’s Portfolio VKTX Stock Details VKTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-6,155	Closed	-$326K	–	599
2024 Q2	$326K	Buy	+6,155	New	+$403K	﹤0.01%	409
2023 Q3	–	Sell	-151,276	Closed	-$2.45M	–	686
2023 Q2	$2.45M	Sell	151,276 -1,546,076	-91%	-$32.4M	0.01%	309
2023 Q1	$28.3M	Buy	1,697,352 +398,352	+31%	+$4.11M	0.19%	113
2022 Q4	$12.2M	Hold	1,299,000	–	–	0.06%	214
2022 Q3	$3.53M	Sell	1,299,000 -24,809	-2%	-$81.3K	0.02%	283
2022 Q2	$3.83M	Buy	+1,323,809	New	+$3.28M	0.06%	191
2018 Q2	–	Sell	-49,986	Closed	-$218K	–	1605
2018 Q1	$218K	Buy	+49,986	New	+$277K	﹤0.01%	1208

Other funds holding VKTX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

Laurion Capital Management's VKTX Position: Q3 2024 in Review

Laurion Capital Management sold out of Viking Therapeutics (VKTX) in Q3 2024, closing a stake of 6,155 shares — an estimated $326K sold.

Laurion Capital Management first reported a position in VKTX in Q1 2018 and held it in 7 quarters. The position peaked at $28.3M in Q1 2023. 422 funds tracked by Wall St. Rank hold VKTX as of Q3 2024.

Laurion Capital Management reported no remaining Viking Therapeutics position as of Q3 2024 after selling out during the quarter.
Laurion Capital Management sold 6,155 Viking Therapeutics shares in Q3 2024, an estimated $326K.
Laurion Capital Management first reported a position in Viking Therapeutics in Q1 2018 and held it in 7 quarters.
Laurion Capital Management's Viking Therapeutics position peaked at $28.3M in Q1 2023.
422 funds tracked by Wall St. Rank held Viking Therapeutics as of Q3 2024.

Based on Laurion Capital Management's 13F filing for Q3 2024, filed 14 Nov 2024.